A Phase 2 interventional study of SLN12140 and Placebo in IgA Nephropathy (IgAN), sponsored by Linno Pharmaceuticals, Inc.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Linno Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 127 studies in Glomerulonephritis, IGA with a site in China — 58 open to participants now, 73 under way, 20 of them phase 3. Glomerulonephritis, IGA · China.
Among the 127 studies in Glomerulonephritis, IGA with a site in China, this one is the 68th largest by planned enrollment of the 109 interventional ones that give a count, is one of 25 that started in 2026, is one of 27 in phase 2, reaches primary completion later than 40 of the 72 other live ones, and was the 111th registered.
276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.
Browse Glomerulonephritis, IGA studies →58 of the 127 studies in Glomerulonephritis, IGA with a site in China are open now. Recruiting first, the newest first:
Hong Zhang · Sites in China
Ages 18–75
Novartis Pharmaceuticals · Sites in China, United States, Colombia and 5 more countries
Ages 2–18
Chengdu Suncadia Medicine Co., Ltd. · Sites in China
Ages 18+
Nanfang Hospital, Southern Medical University · Sites in China
Ages 18–75
ADARx Pharmaceuticals, Inc. · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
127 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 34 · Phase 3 27 · Phase 4 15
First in 2002; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.
Median enrollment 84 across the 109 interventional studies, 537 across the 18 observational. Of the 35 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
57 of 127 have an industry lead sponsor. The 10 most frequent:
Linno Pharmaceuticals, Inc. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Linno Pharmaceuticals, Inc. has 1 study filed under Glomerulonephritis, IGA — fewer than ten, so there is no comparison to draw.
22 of the studies in Glomerulonephritis, IGA with a site in China that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06819826Phase 3Biocity Biopharmaceutics Co., Ltd.A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with Proteinuria | 2026-12-31 |
| NCT06935357Phase 3BiogenA Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN) | 2027-05-31 |
| NCT05852938Phase 3Novartis PharmaceuticalsA Study of Zigakibart in Adults With IgA Nephropathy | 2027-08-10 |
| NCT07014826Phase 3Chengdu Suncadia Medicine Co., Ltd.A Trial of HRS-5965 Capsule in Primary IgA Nephropathy | 2027-10 |
| NCT02954419Sun Yat-sen UniversityIgA Nephropathy Biomarkers Evaluation Study (INTEREST) | 2026-11 |
Add all 22 to your calendar (.ics) → With an account.
Among the 127 studies in Glomerulonephritis, IGA with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, parallel, double-blind, placebo-controlled, subcutaneous administration Phase II dose-exploration clinical trial aimed at evaluating the efficacy, safety, PK, PD, and immunogenicity characteristics of SLN12140 at different doses in IgA nephropathy subjects who have previously received standard treatment (the standard treatment drugs allowed in this study include: angiotensin-converting enzyme inhibitors [ACEi], angiotensin II receptor blockers [ARB], and sodium-glucose co-transporter 2 inhibitors [SGLT2i]) but have poor control.
The study is divided into four stages, including a screening period of up to 8 weeks, an introduction period of up to 12 weeks, a 40-week double-blind period (including a 36-week treatment period and a 4-week safety follow-up period; all subjects in the three dose groups who are willing to continue treatment and are judged by the investigator to potentially benefit from subsequent treatment will enter the open-label extension period for continued treatment after completing the double-blind period), and a 56-week open-label extension period (all subjects in the three dose groups who are willing to continue treatment and are judged by the investigator to potentially benefit from subsequent treatment will continue SLN12140 at the same dose group [the optimal dose], including a 52-week open treatment period and a 4-week safety follow-up period).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SLN12140 by subcutaneous (sc) injection:100mg QW; SLN12140 by subcutaneous (sc) injection:200mg QW; SLN12140 by subcutaneous (sc) injection:600mg Q4W;
Drug: SLN12140
Placebo (0.9% sodium chloride solution) will be provided as an injectable solution without active ingredient for 36 weeks.
Other: Placebo
SLN12140 by subcutaneous (sc) injection:100mg QW for 36 weeks in blind treatment period; SLN12140 by subcutaneous (sc) injection:200mg QW for 36 weeks in blind treatment period; SLN12140 by subcutaneous (sc) injection:600mg Q4W for 36 weeks in blind treatment period; after 36 weeks of blind treatment period, all of subjects will receive SLN12140 treatment for 52 weeks as open-label extension period with one optimal dosage.
Placebo (0.9% sodium chloride solution) will be provided as an injectable solution without active ingredient for 36 weeks in blind treatment period.
Mean change from baseline in urine protein-to-creatinine ratio (UPCR)at Week 36
Change from baseline in Urine protein-to-creatinine ratio (UPCR) by visit.
Time frame: Week 36
Mean change from baseline in urine protein-to-creatinine ratio (UPCR)at Week 24
Change from baseline in Urine protein-to-creatinine ratio (UPCR) by visit.
Time frame: Week 24
Mean change from baseline in urine albumin-to-creatinine ratio (UACR) at Weeks 24, 36;
Change from baseline in Urine albumin-to-creatinine ratio (UACR) by visit.
Time frame: Weeks 24, 36
Mean change from baseline in estimated glomerular filtration rate (eGFR) at Weeks 12, 24, 36
Change from baseline in eGFR by visit
Time frame: Weeks 12, 24, 36
Mean changes from baseline in 24-hour urinary protein excretion (24h-UPE) at weeks 24 and 36.
Time frame: Weeks 24 and 36
Mean changes from baseline in 24-hour urinary albumin excretion (24h-UAE) at weeks 24 and 36.
Time frame: Weeks 24 and 36
Mean changes from baseline in quantitative first morning void (FMV) UPCR at weeks 2, 4, 8, 12, 24, and 36.
Time frame: Weeks 2, 4, 8, 12, 24, and 36.
Mean changes from baseline in quantitative FMV-UACR at weeks 2, 4, 8, 12, 24, and 36.
Time frame: Weeks 2, 4, 8, 12, 24, and 36.
Number and severity of treatment-emergent adverse events
Number and intensity of adverse events
Time frame: 106 weeks
Incidence of treatment-induced anti-drug antibodies
Anti-drug antibody (ADA), incidence, titers and duration
Time frame: Weeks 4、8、12、24、36 and 40
Pharmacokinetics (PK)parameters of SLN12140: Area Under The Plasma Concentration-time Curve
Time frame: Baseline through week 92 (predose and postdose)
PK: Maximum Plasma Concentration (Cmax)
To characterize the pharmacokinetics of SLN12140 in participants with IgAN
Time frame: Baseline through week 92( predose and postdose)
PK: Time To Maximum Concentration (Tmax)
To characterize the pharmacokinetics of SLN12140 in participants with IgAN
Time frame: Baseline through week 92( predose and postdose)
Complement Alternative Pathway (AP) Functional Activity
Serum AP functional activity was measured by the Wieslab functional immunoassay method.
Time frame: Baseline through week 92( predose and post dose)
Complement FP
Plasma FP was measured by enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline through week 92(predose and postdose)
Plan to share: Undecided — It is not decided yet at this moment if we will share IPD with other researchers, or when will IPD will be shared, or with whom will IPD be shared, or by what mechanism will IPD be shared.
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Dec 2027, 19 months later.
Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SLN12140
Linno Pharmaceuticals, Inc.